Compare NKTR & GAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTR | GAB |
|---|---|---|
| Founded | 1990 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1996 | N/A |
| Metric | NKTR | GAB |
|---|---|---|
| Price | $72.79 | $5.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $146.67 | N/A |
| AVG Volume (30 Days) | 481.5K | ★ 590.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.91% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,711,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $33.40 | $5.28 |
| 52 Week High | $109.00 | $6.37 |
| Indicator | NKTR | GAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 46.03 |
| Support Level | $70.24 | $5.60 |
| Resistance Level | $76.49 | $5.72 |
| Average True Range (ATR) | 2.86 | 0.05 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 36.36 | 22.78 |
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.